Houston researchers advance unique nasal vaccine that prevents COVID transmission

cutting spread at the source

The University of Houston's Navin Varadarajan explains that while COVID vaccines prevent advanced disease, they don’t prevent transmission. But he has a solution. Photo via Getty Images

Since the force of COVID-19 hit globally in 2020, scientists have made efficient progress in the fight against it. As Dr. Navin Varadarajan puts it, vaccines have “allowed us to become a society again.”

And he should know, the M.D. Anderson Professor of William A. Brookshire Chemical and Biomolecular Engineering at University of Houston just published back-to-back studies for nasal sprays that combat viruses. One, the NanoSTING therapeutic, has proven effective in treating strains of SARS-CoV-2 and the flu virus. The other, NanoSTING-NS Pan-coronavirus Vaccine is targeted at preventing the transmission of multiple COVID variants altogether.

Why a nasal vaccine? Varadarajan explains that while COVID vaccines prevent advanced disease, they don’t prevent transmission.

“Intramuscular vaccines do not facilitate a component of peer immunity called mucosal immunity, which takes care of these points of entries, these wet surfaces, which can be of the nose and the wet surfaces of the nose, and so they don't prevent transmission,” he tells InnovationMap. “So I can be vaccinated, I pick up a small infection that's confined largely to my nostrils, and I can still pass it on to vulnerable people, the aged, the immunocompromised people who have all the drugs they're taking to fight other things, like cancer patients. And so for them, the vaccines tend to be less efficacious, and if I transfer it to them, unfortunately they can end up in a hospital, right? And so preventing transmission is the way to end this cycle.”

Dr. Navin Varadarajan is the M.D. Anderson Professor of William A. Brookshire Chemical and Biomolecular Engineering at University of Houston. Photo via UH.edu

The NanoSTING-NS is also notable for its potential ability to end what Varadarajan calls “the endless cycle of boosting.” The way to do that, he explains, is to prevent the infection at its root. And theoretically, his lab’s invention could do that. But he cautions readers not to get too excited just yet.

The vaccine is currently in the phase of animal testing, though Varadarajan is hopeful that it could move to human samples in about a year.

The therapeutic can treat multiple respiratory viruses by using fat droplets to deliver the immune booster cGAMP.

“The ability to activate the innate immune system presents an attractive route to armoring humans against multiple respiratory viruses, viral variants and also minimizing transmission to vulnerable people,” says postdoctoral associate Ankita Leekha, first author on the paper that shares NanoSTING’s findings. “The advantage of NanoSTING is that only one dose is required, unlike the antivirals like Tamiflu that require 10 doses.”

Ankita Leekha is the first author on the paper that shares NanoSTING’s findings. Photo via UH.edu

Varadarajan puts it even more simply: “Just like we have Tylenol, just like you take aspirin, you feel like you have some symptoms, and you take it afterwards.”

Currently, he says that the partners with whom the lab is working towards commercialization are prioritizing the therapeutic over the vaccine. The reasons are clear. Varadarajan explains that, while we’ve now long had antibiotics to broadly combat infections, there hasn’t been anything like that to battle viruses. With its ability to target multiple viruses, NanoSTING could be that innovation.

“We activate the innate immune system. So our drug is not virus-specific. Our drug works by activating your own immune system, and that will then fight off different kinds of viruses,” he says.

A single product that treats everything from the common cold to COVID-19 by capitalizing on the patient’s own immune system could be closer than we realize.

The researchers hope to get the vaccine into human trials soon. Photo via UH.edu

From Your Site Articles
What started as a way to bring natural cleaning products in from overseas has turned into a promising application for more sustainable agriculture solutions. Photo via Pexels

Houston entrepreneur brings natural, sustainable cleaning products to US for farm to table application

clean dream

When something is declared clean, one question invariably springs to mind: just how clean is clean?

Then it is, “What metrics decide what’s clean and what’s not?”

To answer those questions, one must abandon the subjective and delve into the scientific — and that’s where Clean Habits come in. The company has science on its side with Synbio, a patented cleaning formula that combines a unique blend of prebiotics and probiotics for their signature five-day clean.

“Actually, we are a synbiotic, which is a prebiotic and a probiotic fused together,” says Kristy Phillips, founder and CEO of Clean Habits. “And that's what gives us the five-day clean, and we also have the longest shelf life — three years — of any probiotic on the market.”

Phillips learned about the European product almost three months before the COVID-19 pandemic. She had heard of probiotics for gut health but had no idea about probiotic cleaning.

“When COVID actually hit, I went back and really started researching the manufacturer who is based in Europe and all of their pre- and probiotic cleaners,” remembers Phillips. “And I just found it to be so interesting that they were using natural probiotics from the dirt, from the soil, from Mother Earth. And they created this entire product line that they have been using for over 15 years. And they had so many clinical trials and hospital studies and university studies that were showing that these probiotic cleaners were working, and they were reducing bacteria, viruses, even viruses in air.

“Not only were they in the cleaning spray sector, but they were also already in water purification. They were in agriculture for animal house farming. They were doing a big trial in the subway station in Milan, putting the probiotics through a big HVAC system. And I just thought, there must be something here.”

Kristy Phillips is the founder and CEO of Clean Habits. Photo via LinkedIn

Phillips was right. After reaching out to the manufacturer, she asked if they had a distributor here in the United States. They didn't.

“Since they didn’t have a distributor here in the U.S., I got the products and tried them out for myself,” says Phillips. “They were chemical-free, non-toxic and eco-friendly and after comparing them side-by-side with the commercial cleaners we all grew up with like the Lysols, bleach, and 409s, I found that the probiotic cleaners not only worked on surface areas to remove bad bacteria and germs, they continued to work for up to five full days at 100 percent.

“The commercial cleaners did kill 99.99 percent of all bacteria and germs, but they only did it for 30 minutes. And then the bacteria and germs start to grow back. And I am like, you know, nobody tells you that in their marketing. So that is what started my journey on the probiotics and creating a line to bring to the market here in the United States.”

Phillips soon realized that her goal was easier said than done.

“I think the U.S. market is one of the hardest to break into,” says the Houston native. “Trying to launch a brand-new product in the United States, in the cleaning sector, you do have to deal with the FDA and the EPA, there is a big game that you must play. And then you do go up against the big boys, like the Johnson and Johnson's of the world. Everybody is so used to chemical cleaning. And to go and try to change that industry and disrupt it, that can be tough for people.

“And at the time, I felt like it was insane because everyone was living in their house due to COVID and continuing to use commercial cleaners that are backed with chemicals. They were all breathing that in. I felt that was doing us all an injustice, especially when you have these probiotics that are natural, non-toxic, non-chemical and safe to breathe. It does change the game.”

Once Phillips noticed that she was not alone, with companies like Jessica Alba’s The Honest Company and Mrs. Meyer’s with their plant-based cleaning products, she forged full speed ahead with Clean Habits.

Now, more than three years later, her company is making a significant impact.

“I said, OK, I’m not crazy here, I must be on the right path,” says Phillips. “With people starting to recognize that there is a better way to clean, we began to get into retailers like Kroger. Right now, we are in the process of on-boarding with Walmart and are in talks with CVS, Whole Foods, and Costco.”

The biggest signal to Phillips that the word was out on Clean Habits came in the form of a potential celebrity endorsement.

“Howie Mandel, who is a certified germaphobe, reached out to us a couple of weeks ago,” says Phillips, who before her mission to clean up the world, was a producer of reality television. “We are about to do a big campaign with him and the Clean Habits line. People know Howie Mandel. So, he is definitely going to bring more awareness to our brand, which will allow us to start a big, heavy push and hopefully we can just capitalize on it and go from there.”

Moving forward, Phillips’ vision for Clean Habits will extend beyond just traditional cleaning products. She sees that she can also have an impact on the industrial and commercial side of things.

“Right now, we are doing testing in agriculture, and this is something that our manufacturers in Europe have already done and they have been extremely successful with it,” says Phillips. “The goal is to see if we could reduce the use of pesticides in farming and replace it with just misting and spraying with the probiotics.

“We already know that by incorporating the probiotics throughout water systems, that we can actually clean the water and take it back to 100 percent natural water or pure water. We can get rid of E. coli, MRSA, staph. And so, we are going to start working with the state of Texas and into animal house cleaning and farming and cleaning their water.”

Additionally, Clean Habits already has research that proves that by incorporating the probiotics, they can start eliminating the bird flu, which affected a lot of Texas chickens recently to where over 350,000 of them had to be put down.

“We’re really trying to change the faith there in agriculture,” says Phillips. “I mean, to me, it's amazing because when I first started this, I was just trying to launch some cleaning supplies, which is fantastic, but this product is so much more than a multi-purpose cleaning spray, your floor cleaner, your drain cleaner or your laundry detergent. This goes into cleaning water, which is everyone's basic right to have clean water. And the fact that we can do it by using these probiotics, to me, my little brain can't compute that part of it.

“And then when we really did start looking into the agriculture and how, by incorporating the probiotics into the animal house, the cleaning of the water, and putting it into their housing system, that we can reduce methane gas by 41 percent. That is huge. This can profoundly change and revolutionize industries. And to be a part of that, and I am so excited.”

While COVID-19 cases are not expected to surge this winter like 2020 and 2021, there are some things you can implement within your business to make sure employees stay healthy through the holidays. Photo via Getty Images

Houston expert: How to keep your workforce healthy this holiday season

guest column

Since the coronavirus pandemic shut down the world economy in March 2020, it has not been business as usual. Last winter presented new challenges to small businesses as the Omicron variant caused a surge in cases and hospitalizations throughout the country, interrupting business once again.

Center for Disease Control (CDC) Director Dr. Anthony Fauci predicted less of a surge this winter than in 2020 and 2021 in a recent White House briefing. The CDC also reports the 32 percent of Americans who remain unvaccinated, whether for personal or medical reasons, remain at greater risk. Cases are not yet trending upward in Texas at a pace for concern, but neighboring New Mexico is experiencing an upswing, as is Arizona, according to data from the Mayo Clinic.

That raises the question, yet again, of how to address the issue with employees nearly three years into the pandemic. Businesses need to evaluate their plans now for a likely increase in coronavirus cases.

Evaluate risk factors

Each small business faces a different risk from a coronavirus surge based on its operations, employees and business model. Unlike bigger corporations, small businesses cannot easily reallocate staff when the coronavirus spreads within the workplace. If an infection spreads to a majority of the team, leanly staffed businesses may need to shut down until employees can return to work.

For businesses producing or distributing consumer or industrial goods, a coronavirus surge in a factory or warehouse could further impact delivery times or disrupt the supply chain. Likewise, independent medical practices, spas or gyms with daily in-person contact could face major impacts in the event of coronavirus spreading between employees and clients. On the other hand, a client services agency like a law firm with a hybrid schedule may face less of a risk, provided sick employees feel well enough to work from home.

Risk will also vary based on vaccination rates, age and health of staff. Employers should be careful to protect employee’s privacy but asking whether an employee is vaccinated does not violate any laws if the question is limited to a yes-or-no answer, according to the U.S. Equal Employment Opportunity Commission. Federal law also does not prohibit employers from requiring all employees to be vaccinated in some circumstances but employers who wish to explore that option should consult with legal counsel to understand the risks.

Finally, businesses need to understand their community risk factors. Find out where weekly coronavirus data is reported within the region and assign responsibility to HR for tracking this data. If cases begin to peak, that could signal growing risk to the business and workers.

Based on the evaluation of risk factors to employees and business operations, determine how a possible surge could impact profitability. If possible, crunch the numbers on revenue and losses for a clear understanding of the financial ramifications. This data will help guide protocols.

Address preventive measures

In the early days of the pandemic, many businesses introduced requirements for employees to test regularly or remain home if experiencing symptoms of the coronavirus. While some businesses have discontinued these policies, they represent a helpful starting point for preventive protocols to implement during another surge.

Businesses who face a significant risk from a coronavirus surge may wish to introduce regular testing at once-a-week intervals, regardless of whether employee show coronavirus symptoms. Communicate to employees about why these protocols are necessary. In July 2022, Pew Research Center found only 41 percent of Americans view the coronavirus as a major threat to public health, down from 67 percent in July 2020. That means employees may take fewer precautions in their own lives and benefit from a reminder of the potential coronavirus impacts to business.

Staggered schedules can further lower the risk of a coronavirus breakout in the workplace, especially for the largest teams on staff. A business with a hybrid remote work policy may divide teams into “pods” where employees only come into the workplace on the same day as other workers in their pod. This approach can contain the potential coronavirus spread to the individuals within the pod while allowing in-person collaboration to continue.

It is important to keep in mind these policies present their own costs in the form of coronavirus test kits, if provided to employees by the business, the cost of employees’ time and possible reduced productivity. Considering these tradeoffs, entirely remote startups or small businesses with less risk of spreading coronavirus between teams may decide against mandatory testing and staggered schedules. Businesses who make that decision should carefully monitor coronavirus data in their communities in case circumstances should change.

Set protocols for illnesses

Regardless of mandatory testing and staggered schedules, all small businesses should put coronavirus policies in place, including how to respond with symptoms present and for those who test positive, but may not have symptoms. When setting policies for those who test positive or someone in their household tests positive, it is important to get the latest information on quarantines from the CDC and communicate these policies clearly with employees.

If vaccination status is unknown, set a rule applying to everyone. Policies to prevent a coronavirus case from spreading include a requirement for exposed employees to work remotely for the quarantine period or wear a mask and socially distance in the workplace. While small businesses and startups often take pride in their flexible approaches, coronavirus policies should be fair and standardized for all.

The worst of the pandemic may be over, and by planning for the likelihood of a winter coronavirus surge, businesses can help ensure it stays that way.

------
Jill Chapman is a director of early talent programs with Insperity, a leading provider of human resources and business performance solutions.

A team out of the engineering school at Rice University has created a technology for real-time wastewater monitoring. Photo via rice.edu

Houston research team snags $2M grant for virus sensing tech

money moves

A team of researchers from Rice University have received a $2 million grant to develop a unique technology that speeds up the analysis of wastewater for viruses from hours to seconds.

The team is based out of Rice’s George R. Brown School of Engineering and led by Rafael Verduzco, associate chair and a professor of chemical and biomolecular engineering and of materials science and nanoengineering. The four-year grant from the National Science Foundation will support the development of the technology, which includes wastewater-testing bioelectric sensors that deliver immediate notice of presence of viruses like SARS-CoV-2, which causes COVID-19, according to a news release from Rice.

The research project — with its partners at the Houston Health Department — have already developed water testing procedures and have analyzed samples from locations around the city. The current process includes taking samples and transferring them to Rice for analysis, but the new technology would be able to monitor systems onsite and instantly. The parties involved with this work are also collaborating with the Centers for Disease Control and Prevention Center of Excellence for wastewater epidemiology that was announced in August.

“Monitoring wastewater for COVID has been pretty effective as a way to get an idea of where we are as a population,” says Verduzco in the release. “But the way it’s done is you have to sample it, you have to do a PCR test and there’s a delay. Our selling point was to get real-time, continuous monitoring to see just how much of this virus is in the wastewater.”

The grant's co-principal investigators include Jonathan Silberg, the Stewart Memorial Professor of BioSciences and director of the Systems, Synthetic and Physical Biology Ph.D. program, and Caroline Ajo-Franklin, a professor of biosciences. Co-investigators also include Lauren Stadler, an assistant professor of civil and environmental engineering, and Kirstin Matthews, a fellow at the Baker Institute for Public Policy.

“These are engineered microbes we’re putting into wastewater, and even though they’re encapsulated, we want to know if there are concerns from health authorities and the general population,” Verduzco said. “Kirstin’s role is to look at the policy side, and also gauge public reaction and educate people about what it means when we talk about engineered bacteria.”

Rafael Verduzco is leading the research and development. Photo by Jeff Fitlow/Rice University

Drs. Maria Elena Bottazzi and Peter Hotez got the green light to distribute their low-cost COVID-19 vaccine in Indonesia. Photo courtesy

Houston doctors get approval for low-cost COVID vaccine abroad

green light

A Houston-born COVID-19 vaccine has gotten the go-ahead to be produced and distributed in Indonesia.

PT Bio Farma, which oversees government-owned pharmaceutical manufacturers in Indonesia, says it’s prepared to make 20 million doses of the IndoVac COVID-19 vaccine this year and 100 million doses a year by 2024. This comes after the vaccine received authorization from the Indonesian Food and Drug Authority for emergency use in adults.

With more than 275 million residents, Indonesia is the world’s fourth most populous country.

IndoVac was created by the Texas Children’s Hospital Center for Vaccine Development and Baylor College of Medicine. Drs. Peter Hotez and Maria Elena Bottazzi lead the vaccine project. Bio Farma is licensing IndoVac from BCM Ventures, the commercial group at the Baylor College of Medicine.

“Access to vaccines in the developing world is critical to the eradication of this virus,” Hotez, co-director of the Texas Children’s Hospital Center for Vaccine Development and dean of the National School of Tropical Medicine at Baylor College of Medicine, says in a news release.

Aside from distributing the vaccine in Indonesia, Bio Farma plans to introduce it to various international markets.

“The need for a safe, effective, low-cost vaccine for middle- to low-income countries is central to the world’s fight against the COVID-19 pandemic,” says Bottazzi, co-director of the Texas Children’s Hospital Center for Vaccine Development and associate dean of the National School of Tropical Medicine at Baylor.

“Without widespread inoculation of populations in the developing world, which must include safe, effective booster doses, additional [COVID-19] variants will develop, hindering the progress achieved by currently available vaccines in the United States and other Western countries.”

Bio Farma says it has completed Phase 1 and Phase 2 clinical trials for IndoVac and is wrapping up a Phase 3 trial.

IndoVac is a version of the patent-free, low-cost Corbevax vaccine, developed in Houston and dubbed “The World’s COVID-19 Vaccine.” The vaccine formula can be licensed by a vaccine producer in any low- or middle-income country, which then can take ownership of it, produce it, name it, and work with government officials to distribute it, Hotez told The Texas Tribune in February.

Among donors that have pitched in money for development of the vaccine are the Houston-based MD Anderson and John S. Dunn foundations, the San Antonio-based Kleberg Foundation, and Austin-based Tito’s Vodka.

“During 2022, we hope to partner with the World Health Organization and other United Nations agencies to vaccinate the world. We believe that global vaccine equity is finally at hand and that it is the only thing that can bring the COVID pandemic to an end,” Hotez and Bottazzi wrote in a December 2021 article for Scientific American.

Drs. Maria Elena Bottazzi and Peter Hotez at the Center for Vaccine Development. Photo courtesy of Texas Children's Hospital

2 Houston powerhouses deploy game-changing COVID-19 worldwide vaccine

a good shot

With the U.S. logging its highest single-day total of new COVID-19 cases (441,278 infections) and some 281, 808, 270 cases documented worldwide, new treatments worldwide are in major demand — especially in emerging nations.

To that end, Texas Children’s Hospital and Baylor College of Medicine announced a new COVID vaccine ready to deploy in India and soon, other underserved countries.

Corbevax, which is dubbed “The World’s COVID-19 Vaccine,” utilizes a traditional recombinant protein-based technology that will enable production at large scales, per a press release. That means the inoculation will be widely accessible to inoculate the global population.

This new vaccine was developed at Texas Children’s Hospital CVD and led by co-directors Drs. Maria Elena Bottazzi and Peter Hotez — and in-licensed from BCM Ventures, Baylor College of Medicine’s integrated commercialization team, to Hyderabad-based vaccine and pharmaceutical company Biological E. Limited (BE).

After completing two Phase III clinical trials involving more than 3000 subjects the vaccine was found to be safe, well tolerated, and immunogenic. Current research shows Corbevax notably effective against the Ancestral-Wuhan strain and the globally dominant Delta variant, press materials note.

Safe, streamlined, low-cost vaccines for middle- to low-income countries are central to the world’s fight against the COVID-19 pandemic, the two Houston organizations note. Indeed, without widespread vaccination of populations in the Global South, additional virus variants will arise, hindering the progress achieved by currently available vaccines in the United States and other Western countries, per research.

“This announcement is an important first step in vaccinating the world and halting the pandemic,” said Hotez in a statement. “Our vaccine technology offers a path to address an unfolding humanitarian crisis, namely the vulnerability the low- and middle-income countries face against the delta variant. Widespread and global vaccination with our Texas Children’s-Baylor-BE vaccine would also forestall the emergence of new variants. We have previously missed that opportunity for the alpha and delta variant. Now is our chance to prevent a new global wave from what might follow.”

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston company wins AHA competition for pediatric heart valve design

winner, winner

Houston-based PolyVascular, which develops minimally invasive solutions for children with congenital heart disease, was named the overall winner of the American Heart Association’s annual Health Tech Competition earlier this month.

The company was founded in 2014 by Dr. Henri Justino and Daniel Harrington and was part of TMCi's 2017 medical device cohort. It is developing the first polymer-based transcatheter pulmonary valve designed specifically for young children, allowing for precise sizing and redilation as the child grows while also avoiding degradation. PolyVascular has completed preclinical studies and is working toward regulatory submissions, an early feasibility study and its first-in-human clinical trial thanks to a recent SBIR grant from the National Heart, Lung, and Blood Institute.

With the new AHA honor, PolyVascular will be invited to join the association’s Center for Health Technology & Innovation Innovators’ Network, which connects entrepreneurs, providers and researchers to share and advance innovation in cardiovascular and brain health.

“This is a tremendous honor for PolyVascular—we’re especially proud to bring hope to families and children living with congenital heart defects,” Justino said in a news release. “Our technology—a minimally invasive valve that can be expanded over time to grow with the child—has the potential to dramatically reduce the need for repeated open-heart surgeries.”

The Health Tech Competition is a live forum for health care innovators to present their digital solutions for treating or preventing cardiovascular diseases and stroke.

Finalists from around the world addressed heart failure, hypertension, congenital heart defects and other issues that exist in cardiovascular, brain and metabolic health. Solutions were evaluated on the criteria of validity, scientific rigor and impact.

The judges included Texas-based Dr. Eric D. Peterson, professor of medicine in the division of cardiology at UT Southwestern Medical Center, and Dr. Asif Ali, clinical associate professor of cardiovascular medicine at the University of Texas Medical School in Houston and director at Cena Research Institute.

According to the American Heart Association, nearly half of U.S. adults live with some form of cardiovascular disease or stroke.

“The American Heart Association plays a pivotal role in advancing innovative care pathways, and we’re excited that our solution aligns with its guidelines and mission,” Justino said in a news release. “It’s time these life-changing technologies reach the youngest patients, just as they already do for adults.”

EO Houston is where ambitious founders go to scale smarter

Don't Go It Alone

Scaling a business from early traction into true growth is one of the most exciting — and punishing — chapters of entrepreneurship. Houston founders know this better than most. Our city is built on ambition: fast-moving industries, talent from around the world, and opportunities that expand as large as the Texas sky.

But as many entrepreneurs eventually learn, scaling isn’t simply “more of what worked.” It requires new systems, new thinking, and often, a new version of the founder. Even the most capable founders eventually face decisions, pressures, and turning points that only other entrepreneurs can truly understand.

Entrepreneurs’ Organization, a global peer-to-peer network of more than 18,000 business owners across 220 chapters in 75+ countries, exists for exactly this stage. One of the largest chapters in the organization, EO Houston brings that global community to life locally, offering founders the connection, learning, and accountability needed to grow sustainably and to grow up as leaders.

A community where founders learn at the highest level
The real value of EO emerges in the lived experiences of other entrepreneurs. When Houston-area founders talk about the moments growth nearly broke their companies, a universal theme appears: you can’t do it alone.

EO Houston member Robert De Los Santos of Sky High Party Rentals learned this the hard way when rapid post-COVID growth made expansion feel limitless — until it wasn’t.

“After COVID, we doubled every year and assumed inventory was the limit. In 2023 we overbought, only to realize demand had peaked. That taught us a hard truth: growth in one city has ceilings. Expanding into Austin and Dallas — the Texas Triangle — gave us new markets to put our inventory to work while we figured out how to penetrate Houston better. The challenge shifted from a strategy of ‘buy more units for demand’ to learning how to tackle the challenges of ‘leading across cities.’”

Founders often enter EO exhausted from trying to maintain control as things grow more complex. Many discover, like Jarred King of Summit Firms, that scaling requires the difficult shift from doing everything to building the team that can.

“We grew quickly because of my network, relationships, and hustle… but I was doing all the work,” King says. “I realized at that point you have to delegate — not just busy work, but important decisions to your key team, as well as set up really effective SOPs.”

“The uncomfortable truth is that you are no longer the best person for most jobs in your company," agrees Darren Randle of Houston Tents & Events. "Your inability to delegate or hire people smarter than you in key leadership and management level roles will become the single biggest drag on the entire business. You have to accept that your original 'hustle' is now a scalability risk."

Making hard decisions, such as walking away from customers or contracts, can feel like less of a sting when you know others have also been faced with tough choices. Aaron Gillaspie of West U's My Salon Suite recalls, “You can’t be everything to everyone, it’s ok to say no, and just understand some customers aren’t the right fit. It’s a two way street and both must win.”

Perspective is perhaps the most important reality check that members find at EO.

“Bigger volume will not make problems go away — you just got to get used to walking the tightrope," says Roger Pombrol of Emerald Standard. "Develop a system for good balance and do not freak out. Scared is no way to live your life. It’s ok if you fall. Your family will still love you. Money is just money. Love is love. The world tries to make you conflate them, but don’t."

Actionable insights from entrepreneurs who’ve already scaled
Conversations like these are happening every month inside EO Forum Meeting. Each EO chapter is divided into several small Forums. These confidential, committed group of 7–10 entrepreneurs who meet to share the real five percent of what they’re experiencing. It’s not advice, but experience — shared candidly, respectfully, and with the kind of vulnerability that leads to breakthroughs.

What makes Forum so impactful is the honesty it draws out. Entrepreneurs are often surrounded by employees, partners, and even family members who rely on them for answers, but seldom do they have a group where vulnerability is not only welcomed, but expected.

Learning experiences that match your ambition
EO supports that growth far beyond peer groups. Through the organization’s global partnerships with institutions like Harvard, Oxford, and INSEAD, Houston members gain access to executive-level learning experiences designed specifically for entrepreneurs.

These programs help founders step out of the day-to-day and think strategically about competitive advantage, innovation, and organizational leadership. Paired with ongoing learning through EO Jumpstart, Nano Learning, and its global library of member-created content, founders stay informed, challenged, and ahead of emerging trends.

And through global communities — ranging from EO Women and EO Under 35 to industry-specific groups — Houston members tap into expertise that spans continents and sectors. Whether someone is navigating M&A, exploring international expansion, or integrating new technologies, the right perspectives are always within reach.

What truly distinguishes EO Houston, however, is its culture. Houston’s entrepreneurial landscape is uniquely diverse and resilient, filled with founders who are hungry to build, innovate, and elevate the city’s business community. EO Houston amplifies that spirit, creating relationships that are as supportive as they are strategic. Many members describe the chapter not simply as a network, but as a catalyst for becoming better leaders, better thinkers, and — just as importantly — better human beings.

Your next level starts here
For entrepreneurs who are ready to scale—beyond their first million, beyond their current comfort zone, and toward a future that requires sharper leadership and stronger community—EO Houston offers an unmatched platform. It is a place where ambitious founders grow faster, think bigger, and gain the confidence to take bold next steps.

If you’re ready to elevate your business and your leadership alongside people who understand the journey, EO Houston is ready to welcome you. Your next level starts with the peers who can help you reach it. Learn more and become a member here.

3 Houston companies land on Deloitte’s Technology Fast 500 list

trending up

Three Houston companies have made this year’s Deloitte North America Technology Fast 500 list.

The report ranks the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America. The Houston companies to make the list, along with their revenue growth rates from 2021-2024, include:

  • No. 16 Action1 Corp., a provider of cybersecurity software. Growth rate: 7,265 percent
  • No. 92 Cart.com, a commerce and logistics platform. Growth rate: 1,053 percent
  • No. 312 Tellihealth, a remote health care platform. Growth rate: 244 percent

“Houston’s unique blend of entrepreneurial energy and innovation continues to strengthen the local business community, and I’m thrilled to see Houston companies honored on the 2025 Deloitte Technology Fast 500 list. Congratulations to all the winners,” said Melinda Yee, managing partner in Deloitte’s Houston office.

Action1 is no stranger to lists like the Deloitte Technology Fast 500. For instance, the company ranked first among software companies and 29th overall on this year’s Inc. 5000, a list of the country’s fastest-growing private companies. Its growth rate from 2021 to 2024 reached 7,188 percent.

Mike Walters, president and co-founder of Action1, said in August that the Inc. 5000 achievement “reflects the dedication of Action1’s global team, who continue to execute against an ambitious vision: a world where cyberattacks exploiting vulnerabilities are entirely prevented across all types of devices, operating systems, and applications.”

Atlanta-based Impericus, operator of an AI-powered platform that connects health care providers with pharmaceutical and life sciences companies, topped the Deloitte list with a 2021-24 growth rate of 29,738 percent.

“Our mission is to set the standard for ethical AI-powered physician connections to pharma resources, accelerating and expanding patient access to needed treatments,” said Dr. Osama Hashmi, a dermatologist who’s co-founder and CEO of Impiricus. “As we continue to innovate quickly, we remain committed to building ethical bridges across this vital ecosystem.”

View All Listings